Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.71 |
| ▸ | HRH1 | P35367 | 3/20 | 0.71 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259795 | 1.00 | MCHR1 (0.71) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| Trifluoroacetic Acid SCHEMBL4255671 | 0.96 | MCHR1 (0.67) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| SCHEMBL4266231 | 0.94 | MCHR1 (0.64) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| SCHEMBL4266225 | 0.94 | MCHR1 (0.64) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| Hydrochloric Acid SCHEMBL4262192 | 0.93 | MCHR1 (0.63) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| Hydrochloric Acid SCHEMBL4262197 | 0.93 | MCHR1 (0.63) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| SCHEMBL4258593 | 0.92 | MCHR1 (0.60) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| SCHEMBL4258595 | 0.92 | MCHR1 (0.60) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| Hydrochloric Acid SCHEMBL4269111 | 0.91 | MCHR1 (0.59) | MCHR1ADRA2AADRA1AHRH1CNR1 | |
| Hydrochloric Acid SCHEMBL4269114 | 0.91 | MCHR1 (0.59) | MCHR1ADRA2AADRA1AHRH1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| EP-1730122-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-12-13 | — | — | EP | claimed |
| WO-2005095357-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | WO | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | MCHR1 3/4885ADRA2A 178/4885ADRA1A 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.